Efficacy of <scp>GLP</scp> ‐1 receptor agonists in patients with obesity and heart failure with preserved ejection fraction: A systematic review and meta‐analysis of randomised controlled trials

Juan Armando TalaveraLarissa TeixeiraBenjamin KleinRaiane Rosa de Souza LopesDaniela Urina‐JassirDenilsa NavalhaBranco Gonzalo Matias BettinottiNicole FernandezMiguel Urina‐TrianaFrancine K. Welty2026-03-222026-03-22202510.1111/dom.70102https://doi.org/10.1111/dom.70102https://andeanlibrary.org/handle/123456789/85749Citaciones: 1GLP-1 RAs significantly reduced heart failure events, improved KCCQ-CSS score, reduced body weight, and improved 6MWD compared to placebo.enMedicineHeart failureHeart failure with preserved ejection fractionInternal medicineCardiologyObesityClinical trialAgonistReceptorRandomized controlled trialEfficacy of <scp>GLP</scp> ‐1 receptor agonists in patients with obesity and heart failure with preserved ejection fraction: A systematic review and meta‐analysis of randomised controlled trialsreview